TP53 and breast carcinoma: When the CM-1 antibody that had been generated against full-length p53 (recognized 1–393 aa, in wild-type and mutant p53 protein forms) was used in our study p53, p53β (48 kDa), ΔNp53 (47 kDa), and Δ133p53β (35 kDa) were detected in breast carcinomas (Figure 6).